- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04124367
IMPULSE - StIMulation of Brain Plasticity to Improve Upper Limb Recovery After StrokE (IMPULSE)
IMPULSE StIMulation of Brain Plasticity to Improve Upper Limb Recovery After StrokE A Prospective, Multi-center, Randomized, Double-blind Study to Assess Efficacy and Safety of Neuroplastic Intervention by Cerebrolysin and atDCS on Motor Function Recovery in Subacute and Chronic Stroke Patients
Stroke is a leading cause of adult long-term disability worldwide. Recovery of arm and hand function after stroke is limited to about 50% of patients and full recovery is achieved in only 12% of stroke survivors by 6 months after stroke. Within the first 8-12 weeks post-stroke, a proportional recovery of 70%, corresponding to good recovery, may be achieved, but at later stages no major gain is observed with current therapy practices. Accordingly, there is a need to find new potential therapeutic tools to enhance post-stroke motor recovery. Rehabilitation supported by neuroplastic intervention is a new and pragmatic therapeutic approach in the treatment of stroke, giving way to a concept of 'recovery enhancers'.
The objective of this study is to assess whether an additional therapy with Cerebrolysin and anodal transcranial direct current stimulation (atDCS) increases the success of conventional rehabilitation therapy in subacute and chronic stroke patients with unexploited potential for functional recovery despite intact structural and functional pathways in the brain.
Hypothesis:
The hypothesis is that the combination of Cerebrolysin and atDCS facilitates motor learning in subacute and chronic stroke patients. Accordingly, motor function recovery at day 21 post-baseline is expected to be higher in the verum group (conventional rehabilitation + task-specific motor training + Cerebrolysin + atDCS) as compared to the control group (conventional rehabilitation + task-specific motor training + placebo + sham-transcranial direct current stimulation).
The primary objective is to show a significantly higher proportional recovery rate in the Action Research Arm Test (ARAT) at day 21 post-baseline in the verum group as compared to the control group.
The secondary objective is to assess the impact of this neuroplastic intervention on finger dexterity (Nine-hole peg test - 9HPT), hand grip strength, and neurological deficits (National Institutes of Healths Stroke Scale - NIHSS) at the end of therapy (day 21 post-baseline). Safety data are collected throughout the study and thereafter in case of ongoing serious adverse events (SAEs) at study endpoint.
Optional secondary parameters include electroencephalography (EEG) parameters and Brain Derived Neurotrophic Factor (BDNF) status analyses to document plastic changes in the brain, in particular changes of the cortical network functionality during neurorehabilitation, and to assess the impact of neuroplastic intervention on the BDNF synthesis rate as well as the influence of different BDNF polymorphisms.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
Bad Pirawarth, Austria, 2222
- Klinik Pirawarth
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- 18-80 years of age, both inclusive, of all sexes
- 8 weeks to 12 months after a first-ever hemispheric subcortical ischemic stroke, confirmed by imaging
- Pre-stroke modified Rankin Scale (mRS) 0 or 1
- Action Research Arm Test (ARAT) score 13-50, both inclusive
- Shoulder Abduction Finger Extension (SAFE) score ≥5
- Patient participates voluntarily and gave written informed consent
Exclusion Criteria:
Disease-related:
o Study procedures:
- Severe sensory deficits (score of 2 on item 8 of the NIHSS)
- Severe aphasia (a score of ≥2 on item 9 of the NIHSS)
- Severe neglect (a score of 2 on item 11 of the NIHSS)
- Co-morbid conditions such as fractures, osteoarthritis, fixed or severely interfering contraction or deformity in the affected limb, polyneuropathy and/or ischemic peripheral disease if the sensorimotor functions of the upper extremities are affected, other neurological disease(s) or known brain abnormalities, acute coronary syndrome, severe heart disease (NYHA class III or IV), cancer, severe liver disease (hepatic disease associated with coagulopathy [prothrombin time prolonged beyond the normal range] and clinically relevant bleeding risk including cirrhotic patients with Child Pugh B and C), and other major medical conditions that, in the opinion of the site investigator, might influence efficacy or safety assessment
- MMSE <20
- Current drug or alcohol use or dependency that would interfere with adherence to study procedures
Participation in another interventional study
- Spasticity:
- Major spasticity as indicated by the Modified Ashworth Spasticity Scale >2/4 in either elbow flexors, wrist flexors or finger flexors of the affected limb
- Injection of botulinum toxin to the affected upper limb in the last three months, or the need of an injection of botulinum toxin anytime during the study period
Injection of phenol to the affected upper limb in the last six months, or the need of an injection of phenol anytime during the study period
Exposure-related:
- Pacemaker or brain stimulator
- Implanted intracranial metals in the stimulation area such as clipping, coilings, ventriculo-peritoneal shunts, endoprosthesis, cochlear implant
- Scalp wounds or infections in the area of stimulation
Any condition that would represent a contraindication for Cerebrolysin administration:
- hypersensitivity to one of the components of the drug
- epilepsy
- severe renal impairment (estimated glomerular filtration rate [eGFR] <30 ml/min/1.73 m2 as assessed at local laboratory within one month before screening)
- Breastfeeding; pregnant or trying to become pregnant
Concomitant medications
- with potential negative effects on cortical excitability or plasticity (e.g. psycholeptics (ATC class N05), antiepileptics, neuroleptics, benzodiazepines, dextromethorphan)
- with potential positive effects on cortical excitability or plasticity (e.g. SSRIs, SNRIs, dopaminergic preparations, memantine, AChEIs, amphetamines) - except if the patient is on a stable dose for a minimum of four weeks. Special attention should be given to possible additive effects when Cerebrolysin is used in conjunction with antidepressants/MAO inhibitors. High doses of MAO inhibitors in combination with higher dosages of Cerebrolysin (30-40 ml) have been reported to increase blood pressure.
- with neuroprotective/neurotrophic/nootropic effects (e.g. ginkgo biloba, erythropoietin, citicoline, amantadine, piracetam)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Control
|
100 ml once daily 0.9% saline
0 mA/35 cm² for 2x20 minutes, once daily Run-in phase consisting of ramp-up (10 seconds), stimulation (10 seconds), and ramp-down (10 seconds).
|
Active Comparator: Verum
|
30 ml once daily (+70 ml 0.9% saline)
2 mA/35 cm² for 2x20 minutes, once daily
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Action Research Arm Test (ARAT)
Time Frame: Day 21
|
The ARAT assesses upper limb functioning.
The ARAT consists of 19 items grouped into four subscales: grasp, grip, pinch, and gross movement.
The total score on the ARAT ranges from 0 to 57, with the lowest score indicating that no movements can be performed, and the upper score indicating normal performance.
|
Day 21
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Nine-Hole Peg Test (NHPT)
Time Frame: Day 21
|
The NHPT is used to measure finger dexterity.
The NHPT is composed of a square board with 9 pegs.
At one end of the board are holes for the pegs to fit in to, and at the other end is a shallow round dish to store the pegs.
The NHPT is administered by asking the patient to take the pegs from a container, one by one, and placing them into the holes on the board, as quickly as possible.
Patients must then remove the pegs from the holes, one by one, and replace them back into the container.
Patients are scored based on the time taken to complete the test activity, recorded in seconds.
|
Day 21
|
Hand grip dynamometry
Time Frame: Day 21
|
Hand grip dynamometry measures grip strength.
The best out of three strength tests of the impaired hand is used as resultant score.
A score is taken with the non-affected hand, followed by the impaired hand.
|
Day 21
|
National Institutes of Health Stroke Scale (NIHSS)
Time Frame: Day 21
|
The NIHSS is a 15-item impairment scale, intended to evaluate neurologic outcome and degree of recovery for patients with stroke.
Total scores on the NIHSS range from 0 - 42, with higher values reflecting more severe cerebral infarcts and correspondingly more severe neurological impairment.
|
Day 21
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Andreas Winkler, MD, MSc, Klinik Pirawarth
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- EVER-AT-0618
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Chronic Stroke
-
The University of Texas Health Science Center,...Recruiting
-
National Yang Ming UniversityCompleted
-
IRCCS San Raffaele RomaIRCCS Sacro Cuore Don Calabria di Negrar; Ospedale Riabilitativo di Alta Specializzazione... and other collaboratorsCompletedCardiovascular Diseases | Vascular Diseases | Cerebrovascular Disorders | Brain Diseases | Central Nervous System Diseases | Acute Stroke | Chronic Stroke | Severe Stroke | Mild StrokeItaly
-
University of Illinois at ChicagoNot yet recruiting
-
VA Office of Research and DevelopmentRecruitingChronic StrokeUnited States
-
University of British ColumbiaCanadian Institutes of Health Research (CIHR); Michael Smith Foundation for...RecruitingStroke | Stroke, Ischemic | Stroke Hemorrhagic | Chronic StrokeCanada
-
Mahidol UniversityRecruitingIschemic Stroke | Hemorrhagic Stroke | Chronic Stroke | Subacute StrokeThailand
-
University of WashingtonRecruitingStroke, Ischemic | Chronic StrokeUnited States
-
IRCCS San Raffaele RomaAzienda Ospedaliero, Universitaria Pisana; I.R.C.C.S. Fondazione Santa Lucia; Fondazione Don Carlo Gnocchi Onlus and other collaboratorsCompletedStroke | Acute Stroke | Chronic StrokeItaly
-
University of LahoreRecruitingChronic Hemorrhagic StrokePakistan
Clinical Trials on Cerebrolysin
-
Ever Neuro Pharma GmbHacromion GmbHCompleted
-
Samsung Medical CenterCompletedCerebrolysinKorea, Republic of
-
Mansoura University Children HospitalCompleted
-
Kwong Wah HospitalCompletedSubarachnoid Hemorrhage | Delayed Cerebral Ischemia | Intracranial Aneurysm | Delayed Ischemic Neurological DeficitChina
-
Sahar M.A. Hassanein, MDCompletedHypoxic-Ischemic EncephalopathyEgypt
-
Clinical Institute of the Brain, RussiaUnknownIschemic StrokeRussian Federation
-
Ain Shams UniversityUnknownMental Handicap | Cerebral Palsy Children | Children With Traumatic Brain Injury | Delayed Speech DevelopmentEgypt
-
Mansoura University Children HospitalCompletedCerebral Palsy | Infant Development | Preterm InfantEgypt
-
Clinical Institute of the Brain, RussiaEver Neuro Pharma GmbH; Nycomed; VeropharmCompleted
-
Hospital Universitario Dr. Jose E. GonzalezEver Neuro Pharma GmbHRecruitingDiabetes Mellitus, Type 2 | Ischemic Stroke, Acute | Blood Brain BarrierMexico